全文获取类型
收费全文 | 186829篇 |
免费 | 18868篇 |
国内免费 | 11132篇 |
专业分类
耳鼻咽喉 | 1738篇 |
儿科学 | 3375篇 |
妇产科学 | 1385篇 |
基础医学 | 12896篇 |
口腔科学 | 4000篇 |
临床医学 | 23633篇 |
内科学 | 17415篇 |
皮肤病学 | 2080篇 |
神经病学 | 4761篇 |
特种医学 | 7178篇 |
外国民族医学 | 15篇 |
外科学 | 16645篇 |
综合类 | 48521篇 |
现状与发展 | 52篇 |
一般理论 | 3篇 |
预防医学 | 20386篇 |
眼科学 | 3010篇 |
药学 | 21775篇 |
254篇 | |
中国医学 | 17919篇 |
肿瘤学 | 9788篇 |
出版年
2024年 | 562篇 |
2023年 | 2441篇 |
2022年 | 5942篇 |
2021年 | 8265篇 |
2020年 | 6933篇 |
2019年 | 4154篇 |
2018年 | 4285篇 |
2017年 | 5585篇 |
2016年 | 4434篇 |
2015年 | 7606篇 |
2014年 | 9891篇 |
2013年 | 12075篇 |
2012年 | 17059篇 |
2011年 | 18264篇 |
2010年 | 15852篇 |
2009年 | 14090篇 |
2008年 | 14715篇 |
2007年 | 14049篇 |
2006年 | 12422篇 |
2005年 | 10026篇 |
2004年 | 7023篇 |
2003年 | 5756篇 |
2002年 | 4420篇 |
2001年 | 3807篇 |
2000年 | 3058篇 |
1999年 | 1367篇 |
1998年 | 458篇 |
1997年 | 465篇 |
1996年 | 396篇 |
1995年 | 315篇 |
1994年 | 292篇 |
1993年 | 148篇 |
1992年 | 126篇 |
1991年 | 116篇 |
1990年 | 99篇 |
1989年 | 56篇 |
1988年 | 59篇 |
1987年 | 67篇 |
1986年 | 33篇 |
1985年 | 37篇 |
1984年 | 22篇 |
1983年 | 21篇 |
1982年 | 18篇 |
1981年 | 4篇 |
1980年 | 2篇 |
1979年 | 3篇 |
1965年 | 3篇 |
1962年 | 2篇 |
1960年 | 2篇 |
1959年 | 2篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
61.
目的:探讨长链非编码RNA(long-chain noncoding,lncRNA)PCGEM1 对肺癌A549 细胞恶性生物学行为的影响及其作用机制。方法:收集2016 年3 月至2018 年5 月湖北医药学院附属太和医院胸外科接受手术治疗的62 例肺癌(lung cancer,LC)患者癌组织及相应的癌旁组织标本,并用以上组织构建LC组织芯片。用qPCR检测lncRNA PCGEM1 及miR-148a 在LC组织相应的癌旁组织及LC细胞株中的表达。构建lncRNA PCGEM1 沉默细胞系A549-siPCGEM1 和阴性对照A549-NC,并以A549 细胞作为空白对照(Control 组),用MTT和平板克隆实验检测敲减PCGEM1 对A549 细胞增殖能力的影响,Transwell 和划痕实验检测敲减PCGEM1 对A549 细胞侵袭和迁移能力的影响。使用生物信息学网站StarBase 预测可互补结合PCGEM1的miRNA,再根据Targetscan 网站预测相应可靶向结合miRNA的基因;Western blotting 实验检测TGF-β2/Smad2 信号通路蛋白表达情况。结果:在LC组织中PCGEM1 的表达水平高于癌旁组织而miR-148a 的表达量明显低于癌旁组织(均P<0.05),PCGEM1 在5 种LC细胞株中的表达明显高于人肺成纤维细胞HLF-02(均P<0.05),且以A549 细胞中表达最高。敲减PCGEM1 后,与Control 组和A549-NC 组比较,A549-siPCGEM1 组A549 细胞增殖、侵袭和迁移能力显著降低(均P<0.05)。StarBase 和Targetscan 网站预测结果显示,PCGEM1 可与miR-148a 互补结合,miR-148a 与TGF-β2 存在靶向结合位点。与Control 组和A549-NC组比较,A549-siPCGEM1 组中miR-148a 表达明显升高,TGF-β2 及p-Smad2 蛋白的表达明显降低(均P<0.05)。结论:lncRNA PCGEM1在LC组织和细胞株中高表达,高表达的PCGEM1 可通过下调miR-148a 水平强化TGF β2/Smad2 信号通路,从而促进A549 细胞恶性生物学行为的进展。 相似文献
62.
Context: Baicalin has many pharmacological activities, including protective function against myocardial ischemia by antioxidant effects and free radical scavenging activity. However, its rapid elimination half-life in plasma and poor water solubility limits its clinical efficacy.Objective: Novel baicalin-loaded PEGylated nanostructured lipid carriers (BN-PEG-NLC) were developed to improve bioavailability of BN, to prolong retention time in vivo and to enhance its protective effect.Methods: In this study, BN-PEG-NLC were prepared by the emulsion-evaporation and low temperature-solidification method using a mixture of glycerol monostearate and polyethylene glycol monostearate as solid lipids, and oleic acid as the liquid lipid. The physicochemical properties of NLC were characterized. The pharmacokinetic and pharmacodynamic behaviors of BN-PEG-NLC or BN-NLC were evaluated in acute MI rats.Results and discussion: The particle size, zeta potential, and entrapment efficiency for BN-PEG-NLC were observed as 83.9?nm, ?32.1?mV, and 83.5%, respectively. The release profiles of BN from both BN-PEG-NLC and BN-NLC were fitted to the Ritger–Peppas modal, which presented burst release initially and prolonged release afterwards. Pharmacokinetics results indicated that BN-PEG-NLC exhibited a 7.2-fold increase in AUC in comparison to BN solution, while a 3-fold increase in comparison to BN-NLC. Biodistribution results revealed that BN-PEG-NLC exhibited higher heart drug concentration compared with BN-NLC as well as BN solution. In the present study, BN-PEG-NLC significantly ameliorated infarct size.Conclusion: The results of the present study imply that PEG-NLC could be the biocompatible carriers for heart-targeted drug delivery to improve myocardial ischemia. 相似文献
63.
目的观察丙泊酚麻醉对老龄大鼠认知功能及海马神经元γ-氨基丁酸A(GABA)受体表达的影响。方法50只SD老年大鼠随机分为丙泊酚组和对照组,每组25只。丙泊酚组大鼠腹腔注射1%丙泊酚中/长链脂肪乳注射液6 mL/kg,对照组腹腔注射等体积的生理盐水。麻醉后1 d进行Morris水迷宫实验,分别采用HE染色和尼氏体染色观察海马区神经细胞及尼氏体(Nissl体)形态学变化,Western Blot检测GABA蛋白量表达。结果麻醉后,2组大鼠肛温、心率、呼吸频率、血氧饱和度比较,差异均无统计学意义(P>0.05)。随着实验时间的延长,2组大鼠逃逸潜伏期、总里程数逐渐减小,丙泊酚组大鼠各时间点逃逸潜伏期、总里程均高于对照组,差异有统计学意义(P<0.05)。丙泊酚组大鼠穿越平台区域次数、时间小于、短于对照组,差异有统计学意义(P<0.05)。对照组海马区Nissl体存在于细胞浆及树突,染色较深,神经细胞排列整齐,形态规则;丙泊酚组Nissl体消失,神经细胞数量减少,细胞核破裂、丢失。丙泊酚组大鼠海马GABA蛋白表达量低于对照组,差异有统计学意义(P<0.05)。结论丙泊酚对大鼠认知功能有影响,并与海马区GABA的表达相关。 相似文献
64.
Platelet function has been described by many laboratory assays, and PL-11 is a new point-of-care platelet function analyzer based on platelet count drop method, which counts platelet before and after the addition of agonists in the citrated whole blood samples. The present study sought to compare PL-11 with other three major more established assays, light transmission aggregometry (LTA), VerifyNow? aspirin system and thromboelastography (TEG), for monitoring the short-term aspirin responses in healthy individuals. Ten healthy young men took 100?mg/d aspirin for 3-day treatment. Platelet function was measured via PL-11, LTA, VerifyNow and TEG, respectively. The blood samples were collected at baseline, 2 hour, 1 day during the aspirin treatment and 1 day, 5?±?1 days, 8?±?1 days after the aspirin withdrawal. Moreover, 90 additional healthy subjects were recruited to establish a reference range for PL-11. Platelet function of healthy subjects decreased significantly 2 hours after 100?mg/d aspirin intake and began to recover during 4–6 days after the aspirin withdrawal. Correlations between methods were PL-11 vs. LTA (r?=?0.614, p?<?0.01); PL-11 vs. VerifyNow (r?=?0.829, p?<?0.01); PL-11 vs. TEG (r?=?0.697, p?<?0.001). There was no significant bias between PL-11 and LTA at baseline (bias?=?1.94%, p?=?0.804) using Bland-Altman analysis, while the data of PL-11 were significantly higher than LTA (bias?=?24.02%, p?<?0.001) during the aspirin therapy. The reference range for PL-11 in healthy young individuals was from 66.8 to 90.5% (95%CI). When aspirin low-responsiveness was defined as LTA?>?20%, the cut-off values for each method were, respectively: PL-11?>?50%, VerifyNow?>?533 ARU, TEG?>?60.2%. The results of different platelet function assays were uninterchangeable for monitoring aspirin response and correlations among them were also varied. Correlations among PL-11 and other three major assays suggested the ability of PL-11 to assess the treatment effects of aspirin. But a large cohort study is needed to confirm the cut-off value of aspirin response detected by PL-11. 相似文献
65.
目的 观察单次9 h高压氧(hyp erbaric oxygen,HBO)治疗对局灶性脑梗死大鼠凋亡诱导因子
(apoptosis-inducing factor,AIF)、线粒体膜电位(mitochondrial membrane potential,MMPo)的影响,探讨
HBO治疗的神经保护作用。
方法 108只SD大鼠制作永久性大脑中动脉闭塞模型,随机分为对照组和HBO组,每组各54只。造
模成功3 h后,HBO组实行HBO干预,压力0.2 MPa持续9 h,对照组呼吸常压空气。采用Garcia评分评估
大鼠神经功能,比较两组造模后13 h、24 h和72 h神经功能改善情况,并在各时间点检测大鼠缺血半
暗带脑组织凋亡细胞数、线粒体和细胞核AIF表达及MMPo水平。
结果 ①神经功能评分:HBO组13 h(P <0.001)、24 h(P =0.04)神经功能评分改善比对照组更明显。
②凋亡细胞数:HBO组13 h、24 h凋亡细胞数较对照组更少(均P <0.001)。③AIF在线粒体和细胞核的
表达:13 h、24 h、72 h各时间点HBO组AI F在线粒体的表达均较对照组多(均P <0.001);各时间点HBO
组AIF在细胞核的表达均较对照组少(均P <0.001)。④MMPo:各时间点HBO组MMPo均高于对照组(均
P <0.001)。
结论 HBO治疗可改善大鼠神经功能,稳定MMPo,抑制AIF由线粒体向细胞核转移可能是其神经保
护作用的机制之一。 相似文献
66.
67.
正Cadmium(Cd), a toxic heavy metal commonly found in the environment, can cause toxic reactions at a dose of 30 mg. Cd is absorbed into the body mainly through the respiratory tract, digestive tract, 相似文献
68.
目的:观察黄连解毒汤对重度颅脑损伤合并肺部感染患者血气指标和炎症因子的影响,探讨其治疗效果。方法:随机抽签方式将77例重度颅脑损伤合并肺部感染患者分为两组。对照组35例接受常规治疗,研究组42例在常规治疗基础上,联合黄连解毒汤直肠灌注及全身擦浴治疗。评估两组临床效果,记录两组呼吸机使用时间、ICU入住时间及治疗费用,测定两组治疗前后血气指标和炎症因子。结果:两组临床治疗效果间差异无统计学意义(P>0.05)。与对照组比,研究组呼吸机使用时间和ICU入住时间明显缩短,ICU治疗费用显著减少(P<0.01)。治疗后两组SaO、PaO2水平明显上升,PaCO2及血清PCT、IL-1β、HMGB-1、CRP水平明显下降(P<0.05)。组间比较,研究组SaO、PaO2水平高于对照组,PaCO2及血清PCT、IL-1β、HMGB-1、CRP水平低于对照组(P<0.05)。结论:黄连解毒汤直肠灌注联合全身擦浴可明显控制重度颅脑损伤合并肺部感染患者感染病症,改善血气指标,调节炎症反应,缩短呼吸机使用时间和ICU入住时间,减少患者的治疗费用。 相似文献
69.
Jie Qian Wei Nie Jun Lu Lele Zhang Yanwei Zhang Bo Zhang Shuyuan Wang Minjuan Hu Jianlin Xu Yuqing Lou Yu Dong Yanjie Niu Bo Yan Runbo Zhong Wei Zhang Tianqing Chu Hua Zhong Baohui Han 《International journal of cancer. Journal international du cancer》2020,146(11):3124-3133
This study aimed to compare the differences in characteristics and prognoses between Asian and white patients receiving immunotherapy for nonsmall cell lung cancer (NSCLC). We studied 390 patients who received atezolizumab as part of the POPLAR or OAK trial, and analyzed the differences in baseline characteristics, outcomes and genetic mutations in blood samples between Asian and white patients. Overall survival (OS) was longer in Asian compared to white patients (median OS: 18.7 vs. 11.1 months; p = 0.005). Race was identified as an independent prognostic factor for OS (Asian vs. white: hazard ratio 0.647, 95% confidence interval 0.447–0.936, p = 0.021), together with performance status, histology, baseline sum of the longest tumor diameters (BLSLD) and number of metastatic sites. The two groups also differed in terms of characteristics including smoking history, BLSLD, epidermal growth factor receptor (EGFR) mutation frequency, programmed death-ligand 1 expression and blood-based tumor-mutation burden. Blood mutations of STK11, EGFR, KEAP1, POLE, GRM3, ATM and STAG2 were associated with treatment response, and TP53, KEAP1, APC, RB1, CREBBP, EPHA5 and STAG2 mutations were associated with OS. The blood-based mutation profiles differentiated between Asian and white patients, especially in relation to EGFR (23.8 vs. 8.5%), TP53 (30.2 vs. 46.9%) and STK11 (1.6 vs. 12.3%) mutations (all p < 0.05). The different clinicopathological features and mutation profiles in Asian and white patients may explain the superior outcome following atezolizumab treatment in Asian patients with NSCLC. The results of this study have important implications for further studies on racial disparities in relation to immunotherapy. 相似文献
70.